Tesamorelin 10mg
Metabolic-path anchor for body-composition and routine goals.
Best For
Routine consistency and metabolic-support goals
What to Review
Compare fit, dosage, and route this formula into a simple routine before checkout.
Secure in-site checkout flow with a focused cart review before order submission
About This Formula
Tesamorelin is a 44-amino acid synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) with a trans-3-hexenoic acid group attached to stabilize it against enzymatic degradation. It is FDA-approved under the brand name Egrifta for the treatment of HIV-associated lipodystrophy, making it one of the few peptides with a clear regulatory approval and clinical trial record. In approved and research contexts, Tesamorelin significantly increases IGF-1 levels and has been shown to reduce visceral adipose tissue (VAT) by approximately 15–20% over 26 weeks, while preserving lean muscle mass.
Key Points
- FDA-approved (Egrifta) for HIV-associated lipodystrophy — one of few approved peptides
- Significantly increases IGF-1 levels through pituitary GH stimulation
- Clinical data: ~15–20% reduction in visceral adipose tissue over 26 weeks
- Preserves lean mass while reducing central fat accumulation in studies
Administration
Subcutaneous injection, typically administered once daily. Requires reconstitution with bacteriostatic water. High-risk tier — professional oversight strongly recommended.
Routine Notes
The clinical approval history makes this one of the more researched GHRH analogues available. Best for those with a specific body-composition goal and medical supervision in place. Not recommended as an entry-level metabolic peptide.